Achieve Life Sciences is a pharmaceutical company that focuses on developing and commercializing cytisinicline for smoking cessation and nicotine addiction. The plant-based alkaloid interacts with nicotine receptors in the brain to reduce the symptoms of nicotine withdrawal. The company has licensing agreements with Sopharma AD and the University of Bristol and is headquartered in Vancouver, Canada.